Treatment with the direct factor Xa inhibitor edoxaban (Lixiana) resulted in low rates of clinically relevant bleeding and thromboembolism (TE) compared with standard-of-care (SOC) anticoagulants in ...

Elderly patients with atrial fibrillation (AF) who are at high risk of bleeding may benefit from a low 15-mg dose of edoxaban, regardless of their frailty status, a subanalysis of the ELDERCARE-AF ...

CHICAGO, IL—Following bioprosthetic valve surgery, anticoagulation with edoxaban (Savaysa; Daiichi Sankyo) is as effective as warfarin, although this strategy might come at a higher cost of bleeding, ...

WASHINGTON, DC—In another negative result for a direct oral anticoagulant in the post-TAVI setting, edoxaban (Savaysa; Daiichi Sankyo) did not have an advantage over dual antiplatelet therapy (DAPT) ...

The anticoagulant edoxaban may be just as effective as warfarin for preventing heart attack or stroke in patients with atrial fibrillation (AF) who undergo transcatheter aortic valve replacement (TAVR ...

It is unclear whether the two once-daily dosing non-vitamin K antagonist oral anticoagulants (NOACs), edoxaban and rivaroxaban, have similar effectiveness and safety in Asian patients with ...

The National Institute for Health and Care Excellence (NICE) has recommended a new treatment to help patients suffering from blood clots in the legs and lungs. NICE has issued a Final Appraisal ...

Please provide your email address to receive an email when new articles are posted on . In an analysis of the ENGAGE AF TIMI-48 trial, researchers compared patients randomly assigned lower-dose ...

Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial ...

Patients with venous thromboembolism (VTE) might benefit from treatment with the novel factor Xa inhibitor edoxaban, according to the results of the Hokusai-VTE trial, which were presented at the 2013 ...

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: final matrix Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - ...

The Appraisal Committee considered evidence submitted by Daiichi Sankyo and a review of this submission by the Evidence Review Group (ERG). The primary source of evidence was ENGAGE AF‑TIMI 48, a ...